Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial Results
StockNews.AI ยท 2 hours
AI Summary
Sonoma posted FY2026 and Q4 2026 results showing 48% quarterly revenue growth and 37% full-year growth, led by a 194% U.S. sales surge. Net loss and EBITDA burn narrowed, aided by new distributors and regulatory wins (MoCRA registration; Medline wound cleanser). Near-term catalysts include expanded distribution and regulatory approvals likely to support revenue and profitability.
Sentiment Rationale
Solid topline growth and narrowing losses may lift sentiment modestly, but ongoing net losses and liquidity risk cap upside in near term; expect range-bound trading until liquidity and profitability visibility improves.
Trading Thesis
Bullish for SNOA in the next 6-12 months as revenue growth accelerates and EBITDA losses narrow, but watch liquidity risk.
Market-Moving
- Q4 2026 revenue rose 48% YoY to $5.6m; FY2026 revenue up 37% to $19.5m.
- US revenue jumped 194% in Q4 and 117% for FY2026.
- Net loss improved 25% in Q4 and 8% for FY2026; EBITDA loss down 66% in Q4 and 38% for the year.
- Cash and cash equivalents were $2.4m as of 3/31/2026; liquidity risk.
Key Facts
- Q4 2026 revenue rose 48% to $5.6m; FY2026 up 37% to $19.5m.
- US revenue up 194% in Q4; 117% for FY2026.
- Net loss down 25% Q4; 8% for FY2026; EBITDA loss down 66% Q4, 38% FY.
- Cash and cash equivalents: $2.4m as of 3/31/2026.
- MoCRA registration and Medline wound cleanser highlight near-term growth.
Companies Mentioned
- Sonoma Pharmaceuticals, Inc. (SNOA): Primary issuer; growth driven by HOCl product lines and regulatory progress.
- Medline Industries, LP (Private): Wound cleanser program; potential distribution expansion in healthcare channels.
- National Psoriasis Foundation (Private): Reliefacyn earned Seal of Recognition, boosting credibility.
- National Rosacea Society (Private): Reliefacyn earned Seal of Acceptance, supporting dermatology market credibility.
Earnings
Category: Earnings. The release details revenue growth, narrowed losses, and non-GAAP EBITDA improvements, plus regulatory/distribution milestones that could drive upside as the company scales HOCl products.